We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Johnson & Johnson, Oracle, Netflix and Espey
Read MoreHide Full Article
For Immediate Release
Chicago, IL – May 21, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ - Free Report) , Oracle Corp. (ORCL - Free Report) , Netflix, Inc. (NFLX - Free Report) and Espey Mfg. & Electronics Corp. (ESP - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Johnson & Johnson, Oracle & Netflix
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Oracle Corp. and Netflix, Inc., as well as a micro-cap stock Espey Mfg. & Electronics Corp.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Johnson & Johnson's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+54.3% vs. +27.2%). The company's Innovative Medicine unit is showing a growth trend, despite loss of exclusivity of Stelara, driven by key products like Darzalex, Tremfya and Erleada and new launches like Spravato, Carvykti and Tecvayli.
The MedTech segment is also showing improved operational growth across several key businesses like Cardiovascular and Surgery. J&J expects sales growth in both segments to be higher in 2026. J&J has also rapidly advanced its pipeline in the past year that will help drive growth through the back half of the decade.
The company has "line of sight" to double-digit top-line growth by the end of the decade. However, the Stelara patent cliff, the impact of Part D redesign and MedTech China issues are key headwinds. The uncertainty around unresolved legal issues lingers.
Shares of Oracle have outperformed the Zacks Computer - Software industry over the past year (+16.6% vs. -9.8%). The company's cloud infrastructure business demonstrates accelerating revenue growth, supported by strategic partnerships and competitive pricing that attract enterprise workload migrations. AI-optimized database capabilities provide technological differentiation, while robust free cash flow generation enables sustained infrastructure investments.
The integrated solutions strategy strengthens customer retention and drives cross-selling opportunities. However, competition from hyperscalers remains intense, potentially pressuring margins. The ongoing transition from license revenue to subscription models creates near-term earnings volatility.
Fiscal 2026 guidance indicates continued cloud acceleration, but execution risks around data center capacity expansion warrant monitoring. Shares have underperformed the industry in the past six-month period.
Netflix's shares have underperformed the Zacks Broadcast Radio and Television industry over the past year (-25.2% vs. -11.5%). The company faces intense competition across streaming and short-form platforms, and growth is expected to moderate versus recent years. Foreign exchange exposure and sizable content obligations, alongside a still-elevated debt balance, limit flexibility and raise execution risk for investors.
Nevertheless, Netflix is expanding beyond subscription streaming into a broader entertainment platform, with advertising, live events, games and video podcasts supporting monetization.
NFLX has set an ambitious target to double its revenues by 2030 and continues to target about $3 billion of advertising revenue in 2026, helped by a larger advertiser base and easier programmatic buying. Content breadth and a global footprint remain key differentiators, while operating margin discipline and rising free cash flow support capital returns over time.
Shares of Espey Mfg. & Electronics have outperformed the Zacks Electronics - Military industry over the past year (+75.8% vs. -35.1%). This microcap company with a market capitalization of $180.59 million is supported by a $137 million backlog that provides multi-year revenue visibility and underpins utilization stability across its vertically integrated operations. Despite lower FY26 sales, margins expanded sharply, driving ~50% net income growth as higher-margin defense programs entered production.
Espey Mfg. & Electronics is positioned to benefit from rising defense modernization spending tied to radar, naval systems, electronic warfare, and UAV applications, while Navy-funded facility upgrades may enhance qualification capabilities and future award competitiveness. A strong balance sheet and sizable dividends further support shareholder returns.
Risks include sharply weaker new-order activity, customer concentration, weaker operating cash flow due to working-capital build, and dependence on U.S. defense budgets. Valuation multiples sit above historical medians.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
The Zacks Analyst Blog Highlights Johnson & Johnson, Oracle, Netflix and Espey
For Immediate Release
Chicago, IL – May 21, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ - Free Report) , Oracle Corp. (ORCL - Free Report) , Netflix, Inc. (NFLX - Free Report) and Espey Mfg. & Electronics Corp. (ESP - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Johnson & Johnson, Oracle & Netflix
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Oracle Corp. and Netflix, Inc., as well as a micro-cap stock Espey Mfg. & Electronics Corp.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Today's Featured Research Reports
Johnson & Johnson's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+54.3% vs. +27.2%). The company's Innovative Medicine unit is showing a growth trend, despite loss of exclusivity of Stelara, driven by key products like Darzalex, Tremfya and Erleada and new launches like Spravato, Carvykti and Tecvayli.
The MedTech segment is also showing improved operational growth across several key businesses like Cardiovascular and Surgery. J&J expects sales growth in both segments to be higher in 2026. J&J has also rapidly advanced its pipeline in the past year that will help drive growth through the back half of the decade.
The company has "line of sight" to double-digit top-line growth by the end of the decade. However, the Stelara patent cliff, the impact of Part D redesign and MedTech China issues are key headwinds. The uncertainty around unresolved legal issues lingers.
(You can read the full research report on Johnson & Johnson here >>>)
Shares of Oracle have outperformed the Zacks Computer - Software industry over the past year (+16.6% vs. -9.8%). The company's cloud infrastructure business demonstrates accelerating revenue growth, supported by strategic partnerships and competitive pricing that attract enterprise workload migrations. AI-optimized database capabilities provide technological differentiation, while robust free cash flow generation enables sustained infrastructure investments.
The integrated solutions strategy strengthens customer retention and drives cross-selling opportunities. However, competition from hyperscalers remains intense, potentially pressuring margins. The ongoing transition from license revenue to subscription models creates near-term earnings volatility.
Fiscal 2026 guidance indicates continued cloud acceleration, but execution risks around data center capacity expansion warrant monitoring. Shares have underperformed the industry in the past six-month period.
(You can read the full research report on Oracle here >>>)
Netflix's shares have underperformed the Zacks Broadcast Radio and Television industry over the past year (-25.2% vs. -11.5%). The company faces intense competition across streaming and short-form platforms, and growth is expected to moderate versus recent years. Foreign exchange exposure and sizable content obligations, alongside a still-elevated debt balance, limit flexibility and raise execution risk for investors.
Nevertheless, Netflix is expanding beyond subscription streaming into a broader entertainment platform, with advertising, live events, games and video podcasts supporting monetization.
NFLX has set an ambitious target to double its revenues by 2030 and continues to target about $3 billion of advertising revenue in 2026, helped by a larger advertiser base and easier programmatic buying. Content breadth and a global footprint remain key differentiators, while operating margin discipline and rising free cash flow support capital returns over time.
(You can read the full research report on Netflix here >>>)
Shares of Espey Mfg. & Electronics have outperformed the Zacks Electronics - Military industry over the past year (+75.8% vs. -35.1%). This microcap company with a market capitalization of $180.59 million is supported by a $137 million backlog that provides multi-year revenue visibility and underpins utilization stability across its vertically integrated operations. Despite lower FY26 sales, margins expanded sharply, driving ~50% net income growth as higher-margin defense programs entered production.
Espey Mfg. & Electronics is positioned to benefit from rising defense modernization spending tied to radar, naval systems, electronic warfare, and UAV applications, while Navy-funded facility upgrades may enhance qualification capabilities and future award competitiveness. A strong balance sheet and sizable dividends further support shareholder returns.
Risks include sharply weaker new-order activity, customer concentration, weaker operating cash flow due to working-capital build, and dependence on U.S. defense budgets. Valuation multiples sit above historical medians.
(You can read the full research report on Espey Mfg. & Electronics here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.